AARD

Aardvark Therapeutics
AARD

12.58 USD
+0.26
2.11%
At close Updated Feb 23, 4:00 PM EST
1 day
2.11%
5 days
4.05%
1 month
-16.19%
3 months
32.42%
6 months
39.16%
Year to date
-4.62%
1 year
-3.45%
5 years
-12.09%
10 years
-12.09%
 

About: Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Employees: 33

Healthcare Biotechnology
0
Funds holding %
of 7,957 funds
Explore Fund Trends
0
Analysts bullish %
of 3 analysts
See Analyst Outlook
0
Positive news %
of 4 articles
Check Journalist POV
Price charts implemented using Lightweight Charts™